Extensive plaque psoriasis successfully treated with adalimumab (Humira®) [19]

British Journal of Dermatology

Volumn 152, Issue 5, 2005, Pages 1091-1092

  Sladden, M J ^a   Mortimer, N J ^a   Hutchinson, P E ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETRETIN; FUMARIC ACID; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; PSORALEN;

CASE REPORT; DRUG EFFECT; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; SIDE EFFECT; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 18944377558     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06582.x     Document Type: Letter

References (2)

1. Chew A-L, Bennett A, Smith CH et al. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 2004; 151:492-6.
2. Chen DM, Gordon K, Leonardi C, Menter AM. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary results from a 12-week dose-ranging trial. J Am Acad Dermatol 2004; 50:P1.